Creation of Diagnostic & Pharmacodynamic Biomarker Groups

Prior to 2005, most biomarker and assay development efforts were spread out in multiple bioanalytical groups and activities were not always coordinated across the organization. In 2004, it was determined that in order to operate more effectively, two biomarker groups should be formed: one to focus on Pharmacodynamic Biomarkers (PDB) and one to focus on Predictive or CDx Biomarkers (MoIDx). In order to ensure alignment and collaboration between the groups, the Diagnostic Subteam System and Diagnostic Review Forums were also created.